Why the study?
Catheter ablation for atrial fibrillation carries both high thromboembolic and bleeding risks, requiring appropriate perioperative anticoagulation management.
Does perioperative DOAC therapy prevent thromboembolism and reduce bleeding complications compared to uninterrupted warfarin in patients with atrial fibrillation undergoing catheter ablation?
Does perioperative DOAC therapy prevent thromboembolism and reduce bleeding complications compared to uninterrupted warfarin in patients with atrial fibrillation undergoing catheter ablation?
Perioperative management with DOACs for atrial fibrillation ablation is safe and effective, offering a convenient alternative to warfarin with potentially lower bleeding risks depending on the specific agent and administration protocol.
Appropriate periprocedural anticoagulation enables safe AF ablation; leaves open optimal DOAC strategies for high-bleeding-risk subgroups.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ken Okumura (2020) conducted a review in Atrial fibrillation. Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: